熱門資訊> 正文
NanoVibronix向股东发出信函
2025-11-19 22:43
- NanoVibronix (NASDAQ:NAOV) announced on Wednesday the issuance of a letter to shareholders, highlighting the company’s strategic vision, market opportunities, and a rebranding initiative.
- To reflect our new strategic direction, the company is planning to rebrand its name from NanoVibronix to ENvue Medical, accompanied by a new NASDAQ ticker symbol.
- The ENvue feeding-tube placement system, which was merged with the company in early 2025, was the strongest and most scalable growth platform.
- ENvue’s potential will be useful in pediatrics and preterm infants, X-ray navigation overlay, vascular access, and robotic tube placement. Together, these opportunities demonstrate that ENvue is more than a single product. It is a broad navigation technology platform with the potential to transform multiple critical-care procedures.
- In the coming weeks, the company will introduce our Board of Directors following our Annual Meeting on December 4, 2025, announce key additions to our leadership team, and share early clinical progress that further validates the impact of ENvue.
More on NanoVibronix
- Seeking Alpha’s Quant Rating on NanoVibronix
- Financial information for NanoVibronix
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
